FibroBiologics Inc. (NASDAQ:FBLG – Get Free Report) was the target of a large growth in short interest in July. As of July 31st, there was short interest totaling 115,200 shares, a growth of 62.6% from the July 15th total of 70,837 shares. Based on an average daily volume of 90,907 shares, the days-to-cover ratio is presently 1.3 days. Approximately 1.9% of the shares of the company are short sold.
FibroBiologics Price Performance
NASDAQ:FBLG traded up $0.12 during midday trading on Tuesday, hitting $1.14. The company’s stock had a trading volume of 301,061 shares, compared to its average volume of 250,110. FibroBiologics has a fifty-two week low of $0.62 and a fifty-two week high of $12.80. The firm has a market cap of $7.59 million, a P/E ratio of -0.22 and a beta of 1.20. The firm’s 50 day moving average is $0.85 and its 200-day moving average is $2.51.
FibroBiologics (NASDAQ:FBLG – Get Free Report) last announced its quarterly earnings data on Friday, July 31st. The company reported ($0.66) EPS for the quarter, beating the consensus estimate of ($0.93) by $0.27. As a group, analysts forecast that FibroBiologics will post -3 EPS for the current year.
Institutional Investors Weigh In On FibroBiologics
Analysts Set New Price Targets
A number of research analysts have issued reports on FBLG shares. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 price target (down from $8.00) on shares of FibroBiologics in a report on Tuesday, August 4th. Weiss Ratings raised shares of FibroBiologics from a “sell (e)” rating to a “sell (e+)” rating in a report on Friday, July 24th. Maxim Group downgraded FibroBiologics from a “buy” rating to a “hold” rating in a research report on Monday, May 4th. Deutsche Bank Aktiengesellschaft lowered FibroBiologics to an “underperform” rating in a research note on Tuesday, August 4th. Finally, Wall Street Zen raised FibroBiologics from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 13th. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Reduce” and a consensus target price of $73.00.
Check Out Our Latest Research Report on FibroBiologics
FibroBiologics Company Profile
FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc was incorporated in 2021 and is based in Houston, Texas.
Featured Stories
- Five stocks we like better than FibroBiologics
- The AI Boom Is Turning This Cable Maker Into a Stock to Watch
- A Star Investor Just Trimmed Amazon—Here’s What It means
- Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look
- Home Depot Analysts See a Path to $375 and Beyond
Receive News & Ratings for FibroBiologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroBiologics and related companies with MarketBeat.com's FREE daily email newsletter.
